Wire · opportunities
Weekly Recap: Phase 3 CagriSema efficacy and FDA decision due Q4
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 October 2026 · Fusion42 review
Novo Nordisk's Phase 3 REDEFINE trial shows CagriSema achieves approximately 25% mean weight loss, with an FDA decision expected in Q4 2026. Despite strong efficacy data, competitive pressure from Eli Lilly's Mounjaro and Zepbound and regional uptake challenges in markets like India temper the drug's outlook.
This Wire brief sits within Fusion42's coverage of Drug Discovery.
◆ ◆ The Wire takeaway
The FDA’s imminent decision on CagriSema will redraw competitive lines in weight-loss therapies, making it urgent for you to position against Eli Lilly’s Mounjaro. You must also adapt your strategy for slower uptake regions like India where acceptance and cost remain tough barriers.
◆ Coverage
1 source · 26 Oct 2026
◆ Related on Wire
◆ Topics